Related Experiment Video
Updated: Jun 26, 2026
Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
Newborn screening for cystic fibrosis
Kevin W Southern1, Marieke M E Mérelle, Jeannette E Dankert-Roelse
1Institute of Child Health, University of Liverpool, Alder Hey Children's Hospital, Eaton Road, Liverpool, Merseyside, UK, L12 2AP. kwsouth@liv.ac.uk
Insights
Newborn screening for cystic fibrosis (CF) shows nutritional benefits and potential for better lung function. However, long-term pulmonary outcomes may be influenced by confounding factors, though screening appears cost-effective.
Area of Science:
- Medical research
- Genetics
- Pediatrics
Background:
- Cystic Fibrosis (CF) is a genetic disorder affecting multiple organs.
- Newborn screening aims to detect CF early for timely intervention.
- The impact of newborn screening on long-term CF outcomes remains a key research question.
Purpose of the Study:
- To evaluate if newborn screening for CF improves clinical outcomes, quality of life, and survival.
- To assess if screening prevents or reduces irreversible organ damage in individuals with CF.
- To determine any adverse effects associated with newborn CF screening.
Main Methods:
- Systematic review of randomized or quasi-randomized controlled trials comparing CF screening to clinical diagnosis.
- Searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register.
- Two independent authors assessed trial eligibility, quality, and extracted data.
Main Results:
- Two trials involving over 1.1 million neonates were eligible; data from one study were analyzed.
- Screened participants showed reduced severe malnutrition and better weight/height percentiles.
- Early pulmonary function and chest radiograph scores were better in screened infants, but long-term outcomes were confounded.
- Earlier colonization with Pseudomonas aeruginosa was observed in screened individuals.
Conclusions:
- Newborn screening for CF demonstrates nutritional benefits and potential for improved pulmonary outcomes.
- Confounding factors significantly influenced long-term pulmonary prognosis in individuals with CF.
- Newborn screening for CF appears to be more cost-effective than traditional diagnosis.
Background:
Does newborn screening for cystic fibrosis (CF) improve clinical outcomes, quality of life and survival?
Objectives:
To examine whether newborn screening for CF prevents or reduces irreversible organ damage and improves clinical outcomes, quality of life and survival in people with CF without unacceptable adverse effects.
Search Strategy:
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from electronic database searches, handsearches of relevant journals and abstract books of conference proceedings.The Group's Trials Register last searched: June 2008.
Selection Criteria:
Randomised or quasi-randomised controlled trials, published and unpublished, comparing screening to clinical diagnosis in people with CF.
Data Collection And Analysis:
Two authors independently assessed trial eligibility and quality and independently extracted data. Allocation concealment was unclear in both studies and sequence generation adequate in one.
Main Results:
Searches identified six trials. Two trials involving 1,124,483 neonates (210 with CF) with a maximum follow up of 17 years were eligible for inclusion. Varying study designs, outcomes reported and summary measures precluded calculation of pooled estimates and only data from one study were analysed. Severe malnutrition was less common among screened participants. Compared with screened participants, the odds ratio of weight below the tenth percentile was 4.12 (95% CI 1.64 to 10.38) and for height was 4.62 (95% CI 1.69 to 12.61) in the control group.At age seven, 88% of screened participants and 75% of controls had lung function parameters within normal limits of at least 89% predicted. At diagnosis chest radiograph scores were significantly better among screened participants; 33% of screened versus 50% of control participants had Wisconsin chest X-ray (WCXR) scores over five (P = 0.097) and 24% of screened versus 45% of control participants had Brasfield chest X-ray (BCXR) scores under 21 (P = 0.042)). Over time, chest radiograph scores were worse in the screened group (WCXR P = 0.017 and BCXR P = 0.041). Results were no longer significant after adjustment for genotype, pancreatic status, and Pseudomonas aeruginosa-culture results. In screened participants colonisation with Pseudomonas aeruginosa occurred earlier. Estimates suggest diagnosis through screening is less expensive.
Authors' Conclusions:
Two randomised controlled trials assessing neonatal screening in CF were identified; data from one study were included. Nutritional benefits are apparent. Screening provides potential for better pulmonary outcomes, but confounding factors influenced long-term pulmonary prognosis of people with CF. Screening seems less expensive than traditional diagnosis.
Related Concept Videos
01:23Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
01:24Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...